Mode
Text Size
Log in / Sign up
Phase 2 Completed N=89 Randomized Treatment

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Source: ClinicalTrials.gov NCT02795429 ↗
Enrolled (actual)
89
Serious AEs
38.2%
Results posted
Jul 2023
Primary outcomePrimary: Phase Ib: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period — 6; 10; 10; 5 Participants

Summary

The purpose of this study of capmatinib (INC280) and spartalizumab (PDR001) was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of spartalizumab administered intravenously (i.v.) as a single agent or in combination with capmatinib administered orally in adult patients with advanced hepatocellular carcinoma (HCC).

Outcome Measures

OutcomeResultp-value
PRIMARY
Phase Ib: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period
6; 10; 10; 5; 7; 10
PRIMARY
Phase Ib: Number of Participants With Dose-Limiting Toxicities (DLTs) During the First 2 Cycles of Treatment
0; 0; 1
PRIMARY
Phase Ib: Number of Participants With Dose Reductions and Dose Interruptions of Capmatinib and Spartalizumab
2; 4; 8; 4; 6; 8
PRIMARY
Phase Ib: Dose Intensity of Capmatinib
391.2; 580.0; 755.6
PRIMARY
Phase Ib: Dose Intensity of Spartalizumab
293.18; 300.00; 300.00
PRIMARY
Phase II: Overall Response Rate (ORR) Per RECIST v1.1
9.4; 10.0
SECONDARY
Phase Ib and Phase II: Best Overall Response (BOR) Per RECIST v1.1
0; 0; 0; 0; 0; 2
SECONDARY
Phase Ib and Phase II: Best Overall Response (BOR) Per irRC
0; 0; 0; 0; 0; 2
SECONDARY
Phase Ib: Overall Response Rate (ORR) Per RECIST v1.1
33.3; 0; 18.2
SECONDARY
Phase Ib and Phase II: Overall Response Rate (ORR) Per irRC
33.3; 0; 27.3; 12.5; 10.0
SECONDARY
Phase Ib and Phase II: Duration of Response (DOR) Per RECIST v1.1
NA; NA; NA; NA
SECONDARY
Phase Ib and Phase II: Duration of Response (DOR) Per irRC
NA; NA; NA; NA
SECONDARY
Phase Ib and Phase II: Time to Response (TTR) Per RECIST v1.1
NA; NA; NA; NA; NA
SECONDARY
Phase Ib and Phase II: Time to Response (TTR) Per irRC
NA; NA; NA; NA; NA
SECONDARY
Phase Ib and Phase II: Progression-Free Survival (PFS) Per RECIST v1.1
3.42; 4.44; 1.35; 2.79; 2.79
SECONDARY
Phase Ib and Phase II: Progression-Free Survival (PFS) Per irRC
3.42; 4.44; 5.55; 3.06; 2.79
SECONDARY
Phase Ib and Phase II: Time to Progression (TTP) Per RECIST v1.1
3.42; 4.44; 1.35; 2.79; 2.79
SECONDARY
Phase Ib and Phase II: Time to Progression (TTP) Per irRC
3.42; 4.44; 5.55; 3.06; 2.79
SECONDARY
Phase Ib and Phase II: Overall Survival (OS)
14.98; 12.11; 16.53; 14.88; 9.78
SECONDARY
Phase II: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period
32; 30; 30; 18; 25; 15
SECONDARY
Phase II: Number of Participants With Dose Reductions and Dose Interruptions of Capmatinib and Spartalizumab
18; 22; 0; 0; 12; 13
SECONDARY
Phase II: Dose Intensity of Capmatinib
696.4
SECONDARY
Phase II: Dose Intensity of Spartalizumab
300.00; 300.00
SECONDARY
Phase Ib: Maximum Observed Plasma Concentration (Cmax) of Capmatinib
1680; 3110; 4980
SECONDARY
Phase Ib: Time to Reach Maximum Plasma Concentration (Tmax) of Capmatinib
0.959; 1.00; 1.00
SECONDARY
Phase Ib: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Capmatinib
5740; 8570; 16000
SECONDARY
Phase II: Pre-dose Plasma Concentration of Capmatinib
607; 345; 410; 363; 275
SECONDARY
Phase Ib and Phase II: Maximum Observed Serum Concentration (Cmax) of Spartalizumab
75.7; 77.2; 84.7; 81.7; 72.8; 105
SECONDARY
Phase Ib and Phase II: Time to Reach Maximum Serum Concentration (Tmax) of Spartalizumab
1.51; 1.50; 1.50; 1.64; 1.59; 1.53
SECONDARY
Phase Ib and Phase II: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Spartalizumab
739; 726; 813; 805; 693; 1280
SECONDARY
Phase Ib and Phase II: Percent Marker Area for CD8 Expression in Tumor Samples
0.6; 0.9; 0.4; 0.5; 0.3; 3.0
SECONDARY
Phase Ib and Phase II: PD-L1 Percent Positive Tumor
0.0; 0.0; 0.0; 0.0; 0.0; 12.5

Eligibility Criteria

Inclusion Criteria

  • Histologically or cytologically documented locally advanced recurrent or metastatic HCC or for patients with cirrhosis according to the American Association for the Study of Liver Diseases (AASLD) and Asian Pacific Association for the study of the liver (APASL) criteria. Current cirrhotic status of Child Pugh Class A (5-6 points), with no encephalopathy and/or clinically significant ascites (defined as requiring the use of diuretics or paracentesis treatment).
  • Patients must have received prior systemic sorafenib treatment for HCC with documented progression during or after discontinuation of sorafenib treatment (for France only: patients must have received at least 8 weeks of prior sorafenib treatment), or are intolerant to sorafenib (defined as documented Grade 3 or 4 adverse events that led to sorafenib discontinuation),.
  • ECOG Performance Status ≤ 1.
  • Willing and able to swallow and retain oral medication.

Exclusion Criteria

  • Use of any live vaccines within 4 weeks of initiation of study treatment.
  • History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).
  • Clinically significant pleural effusion that either required pleurocentesis or is associated with shortness of breath.
  • Active autoimmune disease or a documented history of autoimmune disease.
  • Clinically significant, uncontrolled heart diseases.
  • Patient having out of range laboratory values defined as:
  • Total bilirubin > 2 mg/dL, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN
  • Alanine aminotransferase (ALT) > 5 x ULN
  • Aspartate aminotransferase (AST) > 5 x ULN
  • Coagulation: Prothrombin Time (PT) > 4 seconds more than the ULN or International Normalized Ratio (INR) > 1.7
  • Absolute neutrophil count (ANC) 2 (1.5-2.0 x ULN). Patients with grade 1 or grade 2 serum amylase at the beginning of the study must be confirmed to have no signs or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.)
  • Serum lipase > ULN
  • Potassium, Magnesium, Phosphorus, total Calcium (corrected for serum albumin) outside of normal limits (patients may be enrolled if corrected to within normal limits with supplements during screening)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02795429). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search